Recommendations for the use of biologic (TNF-α blocking) agents in the treatment of rheumatoid arthritis in Italy

被引：0
作者：
Valesini, G.
Montecucco, C.
Cutolo, M.
机构：
[1] Univ Roma La Sapienza, Cattedra Reumatol, Rome, Italy
[2] Univ Pavia, I-27100 Pavia, Italy
[3] Univ Genoa, Genoa, Italy
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2006年 / 24卷 / 04期
关键词：
rheumatoid arthritis; anti-TNF; biological agents; management; recommendations;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The present report is devoted to drawing up and disseminating specific recommendations for the use of anti-TNF-alpha therapies in patients with rheumatoid arthritis (RA) in Italy. The document reports and discusses the published literature concerning the criteria for inclusion, assessment of response and for withdrawal of treatment with TNF blocking agents in RA. Several specific points concerning more sensitive warnings are discussed: tuberculosis, hepatitis, lymphoma, and cardiovascular risk and induction of autoimmunity. The recommendations are summarized in an 8-point table approved by the executive committee of the Italian Society for Rheumatology.
引用
收藏
页码：413 / 423
页数：11
相关论文
共 110 条
  • [1] Socio-economic consequences of rheumatoid arthritis in the first years of the disease
    Albers, JMC
    Kuper, HH
    van Riel, PLCM
    Prevoo, MLL
    Van't Hof, MA
    van Gestel, AM
    Severens, JL
    [J]. RHEUMATOLOGY, 1999, 38 (05) : 423 - 430
  • [2] Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFα therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement
    Alessandri, C
    Bombardieri, M
    Papa, N
    Cinquini, M
    Magrini, L
    Tincani, A
    Valesini, G
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (10) : 1218 - 1221
  • [3] Allanore Y, 2004, CLIN EXP RHEUMATOL, V22, P756
  • [4] How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH
    Anker, SD
    Coats, AJS
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2002, 86 (2-3) : 123 - 130
  • [5] [Anonymous], GAZZETTA UFFICIALE
  • [6] Haematopoietic malignancies in rheumatoid arthritis:: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists
    Askling, J
    Fored, CM
    Baecklund, E
    Brandt, L
    Backlin, C
    Ekbom, A
    Sundström, C
    Bertilsson, L
    Cöster, L
    Geborek, P
    Jacobsson, LT
    Lindblad, S
    Lysholm, J
    Rantapää-Dahlqvist, S
    Saxne, T
    Klareskog, L
    Feltelius, N
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) : 1414 - 1420
  • [7] Lymphoma subtypes in patients with rheumatoid arthritis -: Increased proportion of diffuse large B cell lymphoma
    Baecklund, E
    Sundström, C
    Ekbom, A
    Catrina, AI
    Biberfeld, P
    Feltelius, N
    Klareskog, L
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (06): : 1543 - 1550
  • [8] Disease activity and risk of lymphoma in patients with rheumatoid arthritis:: nested case-control study
    Baecklund, E
    Ekbom, A
    Sparén, P
    Feltelius, N
    Klareskog, L
    [J]. BRITISH MEDICAL JOURNAL, 1998, 317 (7152) : 180 - 181
  • [9] Adalimumab - A review of its use in rheumatoid arthritis
    Bang, LM
    Keating, GM
    [J]. BIODRUGS, 2004, 18 (02) : 121 - 139
  • [10] A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
    Bathon, JM
    Martin, RW
    Fleischmann, RM
    Tesser, JR
    Schiff, MH
    Keystone, EC
    Genovese, MC
    Wasko, MC
    Moreland, LW
    Weaver, AL
    Markenson, J
    Finck, BK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) : 1586 - 1593
12345678910